IB

International BM Biomedicine Holdings AG

Europe, Basel-Stadt, Switzerland, Basel

Description

International BM Biomedicine Holdings AG invests in biopharmaceutical companies located in the United States.

Investor Profile

International BM Biomedicine Holdings AG has made 2 investments, with 0 in the past 12 months and 50% as lead.

Stage Focus

  • Series B (100%)

Country Focus

  • United States (100%)

Industry Focus

  • Innovation Management
  • Medical
  • Professional Services
  • Biopharma
  • Biotechnology
  • Health Care
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does International BM Biomedicine Holdings AG frequently co-invest with?

HBM Healthcare Investments
Europe, Zug, Switzerland, Zug
Co-Investments: 1
DeNovo Ventures
North America, California, United States, Saratoga
Co-Investments: 1
Duke University
North America, North Carolina, United States, Durham
Co-Investments: 1
Bosch Capital
Europe, Moscow City, Russian Federation, Moscow
Co-Investments: 1
Skyline Ventures
North America, California, United States, Palo Alto
Co-Investments: 1
BioVeda Capital
Asia, Central Region, Singapore, Singapore
Co-Investments: 1
Alta Partners
North America, Mississippi, United States, Jackson
Co-Investments: 1
Yasuda Enterprise Development
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
Venrock
North America, California, United States, Palo Alto
Co-Investments: 1
Flagship Pioneering
North America, Massachusetts, United States, Cambridge
Co-Investments: 1

What are some of recent deals done by International BM Biomedicine Holdings AG?

Renovis

South San Francisco, California, United States

Renovis,is a biopharmaceutical company developing drugs to treat neurological diseases and disorders.

Innovation ManagementMedicalProfessional Services
Series BJan 10, 2002
Amount Raised: $34,300,000
Cytokinetics

South San Francisco, California, United States

Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.

BiopharmaBiotechnologyHealth Care
Series BOct 12, 1999
Amount Raised: $20,000,000